Mouse Anti-Human DLX4 Antibodies
- Known as:
- Mouse Antibody toHuman DLX4 Antibodies
- Catalog number:
- JI-04-00659
- Product Quantity:
- 502 μg
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Mouse Anti-Human DLX4 Antibodies
Related genes to: Mouse Anti-Human DLX4 Antibodies
- Gene:
- DLX4 NIH gene
- Name:
- distal-less homeobox 4
- Previous symbol:
- DLX7, DLX9
- Synonyms:
- DLX8, BP1
- Chromosome:
- 17q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1996-08-07
- Date modifiied:
- 2016-10-25
Related products to: Mouse Anti-Human DLX4 Antibodies
Related articles to: Mouse Anti-Human DLX4 Antibodies
- Distal - less homeobox 4 (DLX4) is a transcription factor vital for embryonic development and shows pro - oncogenic properties in some hematological and solid tumors. In colorectal cancer (CRC), its molecular function and contributions to tumorigenesis remain to be explored. Using bulk, single - cell and spatial transcriptomics, we assessed DLX4’s clinicopathological significance and its impact on the tumor immune microenvironment (TIME). Our results show DLX4 is highly expressed in CRC, correlating with poor prognosis in multi - center cohorts and is also related to a cytotoxic T lymphocyte (CTL) dysfunction - related immunosuppressive microenvironment. Transcriptomic and proteomic analyses identified DLX4 - associated cell signaling. In vitro, we confirmed DLX4 promotes cell proliferation, cell - cycle transitions and suppresses apoptosis. Furthermore, we found its key transcriptional target ZC3HC1 via ChIP – seq analysis, ChIP - qPCR and luciferase assay. Notably, DLX4 has strong potential for liquid - liquid phase separation and likely forms condensates when binding to ZC3HC1’s promoter, a crucial cell - cycle regulator. Overall, DLX4 is a novel prognostic biomarker and suggests potential CRC therapeutic strategies, making significant contributions to the understanding and potential treatment of CRC at the molecular level. - Source: PubMed
Publication date: 2025/10/22
Cheng JingsongZhang ChengxiLuo YimanChen YihanChen NantingWan YuanyuanHuang XinyuZheng ZihengYin QingyaoChen XueHua JingLi YangHuang Rongzhong - The fibroblast-like synoviocyte (FLS) has a central role in rheumatoid arthritis (RA) pathogenesis and its invasive behavior strongly correlates with disease severity and joint damage. Yet, the regulation of FLS invasiveness is incompletely understood. Distal-less homeobox 4 (DLX4) is a transcription factor implicated in cancer cell invasion and metastasis, and we considered that it might also be involved in the regulation of FLS phenotypes. siRNA was used to knockdown DLX4 in RA FLS, compared with a control siRNA. Cells were then studied in invasion, migration, proliferation and adhesion assays, and RNA was used for RNA sequencing and pathway analyses. siRNA knockdown of DLX4 significantly reduced RA FLS invasiveness (P = 0.028) and migration in the scratch/wound healing assay (P = 0.008). RNA sequencing analyses revealed that DLX4 knockdown significantly affected processes and pathways implicated genes involved in diverse types of cancer and in cancer biology, including cell invasion, cell cycle, DNA replication, transcription, p53 signal transduction, RHO GTPase signaling, regulation of cytokinesis, as well as response to oxygen levels and to oxidative stress. HMOX1 and SOD2 were among the genes with the most significantly increased expression, while CPNE3 and HADHA were among those with the most significantly decreased expression in FLS knocked down for DLX4 compared with controls. We describe a new role for DLX4 in the regulation of RA FLS behaviors relevant to disease pathogenesis and joint damage, and identify a new transcriptomic signature regulated by this gene. These findings raise the possibility that DLX4, or one of its target genes and pathways may become a target for treatment. - Source: PubMed
Publication date: 2025/07/11
Laragione TeresinaHarris CarolynGulko Percio S - DLX4 is involved in the regulation of embryonic development, but its function in cancer remains unclear. Here, we conducted a pan-cancer analysis to investigate the molecular mechanisms of DLX4, with a particular emphasis on its role in renal cancer. - Source: PubMed
Publication date: 2025/04/05
Kou ZengshunZhu ShuaizhiZhu JiaxiWang ShufeiZheng YuZhou ShengjieSi Zi'angZhu Hai - Short-term and long-term adverse events could occur after general anesthesia (GA) and the specific mechanism driving these effects has not yet been well-characterized. In this study, we aimed to evaluate the global effect of GA on DNA methylation in the cell-free DNA (cfDNA) of surgical lung-nodule patients. - Source: PubMed
Publication date: 2024/11/13
Liang WenhuaLiu XinChen ZhuxingWang HaixuanYu ZiwenLi ChunyanYang HaoTao JinshengLi HuiChen ZhiweiFan Jian-BingHe Jianxing - This meta-analysis explored genes in common between breast cancer (BC) and colorectal cancer (CRC) in women. Breast cancer and CRC are causes of significant morbidity and mortality in women worldwide. Research has shown that women are underrepresented in clinical trials, especially in oncology; studying sex differences in cancer addresses this lack. - Source: PubMed
Aguilar-García Xavier JLuna-Alvear Alibeth ENarváez-Bandera IsisSuárez-Gómez DeiverIsaza Clara ECabrera-Rios Mauricio